Anti-Human IL-6 Azide Free
855.050.000 - 200µg / 200µl
Recognises both natural and recombinant human IL-6
B-E8
Functional assay
Recombinant human IL-6
200µg or 500µg (Discovery Size also available please enquire)
Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free
Inhibits IL-6 induced proliferation on XG1 cell line
Graph 1: XG1 cell proliferation measurement with resazurin after 96 hours with IL-6 (1ng/ml) and different concentrations of antibody.
Graph 2: Activated monocytes marked with B-E8
Graph 3: B-E8 with non-activated monocytes
In the two cases, the dotted line represents the IgG1 isotype control
Moreau, P. et al., Blood (ASH Annual Meeting Abstracts)2008; 112(11): 1126
Srivani, R. et al., Current Science,2003; 84(3):434-438
Adam, N. et al., J. Virol.,2009; JVI.01601-08. - Pubmed link
Ancey, C. et al., Cardiovasc Res.,2003; 59(1): 78-85. - Pubmed link
Autissier, P. et al., Int Immunol.,1998; 10(12): 1881-9. - Pubmed link
Bataille, R. et al., Blood,1995; 86(2): 685-91. - Pubmed link
Bataille, R. et al., Med Oncol Tumor Pharmacother.,1993; 10(4): 185-8. - Pubmed link
Beck, J. T. et al., N Engl J Med.,1994; 330(9): 602-5. - Pubmed link
Blay, J. Y. et al., Blood,1993; 82(7): 2261-2. - Pubmed link
Blay, J. Y. et al., Int J Cancer,1997; 72(3): 424-30. - Pubmed link
Burger, R. et al.,Haematologica, 2017;102(2) :381-390 - Pubmed link
Burger, R.,Transfus Med Hemother.,2013; 40(5): 336-43 - Pubmed link
Choudhary, M.M. et al.,World J Otorhinolaryngol Head Neck Surg. 2016 Jul 20;2(2):90-97. - Pubmed link
Choy, E. H. et al., Br J Rheumatol.,1995; 34(8): 707-15. - Pubmed link
Choy, E., Ann Rheum Dis.,2003; 62 Suppl 2: ii68-9. - Pubmed link
Corbellino M. et al., Blood, 2001; 98(12): 3473 - 3475 - Pubmed link
Defacque, H. et al., J Pharmacol Exp Ther.,1994; 271(1): 193-9. - Pubmed link
Delneste Y. et al., Blood, 2003; 101(1): 143 - 150 - Pubmed link
Derenne S. et al., Blood 2002; 100(1) : 194 - 199 - Pubmed link
Derhaschnig, U. et al., Crit Care Med.,2004; 32(5): 1136-40. - Pubmed link
Dore, P. et al., Clin Exp Immunol.,1997; 107(1): 182-8. - Pubmed link
Durandy, A. et al., J Immunol.,1994; 152(11): 5361-7. - Pubmed link
Emilie, D. et al., Blood,1994; 84(8): 2472-9. - Pubmed link
Foussat, A. et al., Eur Cytokine Netw.,1999; 10(4): 501-8. - Pubmed link
Garban, F. et al., Blood,2006; 107(9): 3474-80. - Pubmed link
Gougelet, A. et al.,PLoS One,2009; 4(11): e8026 - Pubmed link
Gu, Z. J. et al., Blood,1996; 88(10): 3972-86. - Pubmed link
Gu, Z. J. et al., Leukemia,2000; 14(1): 188-97. - Pubmed link
Haddad E. et al., Blood, 2001; 97(6): 1590 - 1597 - Pubmed link
Jego G. et al., Blood, 2001; 97(6) : 1817 - 1822 - Pubmed link
Jego, G. et al., Blood,1999; 94(2): 701-12. - Pubmed link
Jourdan, M. et al., Br J Haematol.,1998; 100(4): 637-46. - Pubmed link
Jourdan, M. et al., Eur Cytokine Netw.,1999; 10(1): 65-70 - Pubmed link
Jourdan, M. et al., J Immunol.,1991; 147(12): 4402-7. - Pubmed link
Kalai, M. et al., Blood,1997; 89(4): 1319-33. - Pubmed link
Kap, Y. S. et al., Journal of Histochemistry & Cytochemistry,2009;57(12):1159-1167. - Pubmed link
Klein, B. et al., Blood,1991; 78(5): 1198-204. - Pubmed link
Kricka, L. J., Clin Chem.,1999; 45(7): 942-56. - Pubmed link
Kube, D. et al., Blood,2001; 98(3): 762-70. - Pubmed link
Leblond, V. et al., J Clin Oncol.,2001; 19(3): 772-8. - Pubmed link
Legouffe, E. et al., Clin Exp Immunol.,1994; 98(2): 323-9. - Pubmed link
Lelievre, E. et al., Cytokine,1998; 10(11): 831-40. - Pubmed link
Llorente, L. et al., J Exp Med.,1995; 181(3): 839-44. - Pubmed link
Lu, Z. Y. et al., Blood,1995; 85(9): 2521-7. - Pubmed link
Lu, Z. Y. et al., Blood,1995; 86(8): 3123-31. - Pubmed link
Lu, Z. Y. et al., Cytokine,1993; 5(6): 578-82. - Pubmed link
Lu, Z. Y. et al., Eur J Immunol.,1992; 22(11): 2819-24. - Pubmed link
Mahtouk K. et al., Blood, 2004; 103(5): 1829 - Pubmed link
Mahtouk, K. et al., Oncogene,2005; 24(21): 3512-24. - Pubmed link
Marfaing-Koka, A. et al., J Acquir Immune Defic Syndr Hum Retrovirol.,1996; 11(1): 59-68. - Pubmed link
Menetrier-Caux C. et al., Blood, 1998; 92(12) : 4778 - 4791 - Pubmed link
Menetrier-Caux, C. et al., Cancer Res.,2001; 61(7): 3096-104. - Pubmed link
Montero-Julian, F. A. et al., J Interferon Res.,1994; 14(5): 301-2. - Pubmed link
Moreau P. et al., Blood, 2006; 107 (1) :397-403 - Pubmed link
Moreau P. et al., Br. J. Haematol., 2000; 109(3) : 661-664 - Pubmed link
Moreaux J. et al., Blood, 2004; 103(8) : 3148 - 3157 - Pubmed link
Okamoto, W. et al.,Br J Cancer,2011; 105(3): 407-12 - Pubmed link
Park, C. S. et al., Am J Respir Crit Care Med.,2000; 162(3 Pt 1): 1162-8. - Pubmed link
Pieraut, S. et al., J. Neurosci., 2011; 31: 13516 - 13526 - Pubmed link
Racadot, E. et al., Cytokines Mol Ther.,1995; 1(2): 133-8. - Pubmed link
Sanceau, J. et al., J Immunol.,1991; 147(8): 2630-7. - Pubmed link
Smith, M. D. et al., Ann Rheum Dis.,2003; 62(4): 303-7. - Pubmed link
Song, X. Y. et al., Mol Interv.,2002; 2(1): 36-46. - Pubmed link
Sprynski, A. C. et al., Blood,2009; blood-2008-07-170464. - Pubmed link
Sprynski, A. C. et al.,Leukemia,2010; 24(11): 1940-50. - Pubmed link
Stenger, S. et al., J Immunol.,1998; 161(7): 3582-8. - Pubmed link
Tarte, K. et al., Br J Haematol.,2004; 125(3): 373-82. - Pubmed link
Wendling, D. et al., Br J Rheumatol.,1996; 35(12): 1330. - Pubmed link
Wijdenes, J. et al., Mol Immunol.,1991; 28(11): 1183-92. - Pubmed link
Zhang, X. G. et al., Blood,1994; 83(12): 3654-63. - Pubmed link
Zhang, X. G. et al., Cancer,1992; 69(6): 1373-6. - Pubmed link
855.052.019 - Anti-Human IL-6 PE Conjugated
855.060.000 - Anti-Human IL-6 Azide Free
879.030.001 - Anti-Human IL-6 Capture Antibody
879.030.002 - Anti-Human IL-6 Detection Antibody
856.021.001 - Human IL-6 ELISpot Set
856.021.001PC - Human IL-6 ELISpot Kit
670.010.096 - Rat IL-6 ELISA Kit
860.020.048 - Murine IL-6 ELISA Kit
950.030.048 - Human IL-6 ELISA Kit
950.035.048 - Human IL-6 High Sensitivity ELISA Kit
851.520.001 - Human IL-6 ELISA Set
861.020.001 - Murine IL-6 ELISA Set
869.020.010 - Human IL-6 ELISpot Pair
715-H01-010-BSA - Recombinant Human Interleukin-6 (IL-6)-BSA
715-H01-010-CF - Recombinant Human Interleukin-6 (IL-6)-CF
Interleukin-6 (IL-6) is a multi-functional cytokine that regulates immune responses, acute phase reactions and hematopoiesis and may play a central role in host defense mechanisms. The gene for human IL-6 has been localized to chromosome 7p21. The genomic sequence has been determined. IL-6 is usually not produced constitutively by normal cells, but its expression is readily induced by a variety of cytokines, lipopolysaccharide or viral infections. The IL-6 gene product is a single chain protein with a molecular mass ranging from 21 to 28 kDa, depending on the cellular source. Extensive posttranslational modifications like N- and O-linked glycosylation as well as phosphorylation seem to account for this heterogeneity. The cDNA for IL-6 predicts a precursor protein of 212 amino acids. IL-6 is a pleiotropic cytokine produced by a variety of cells. It acts on a wide range of tissues, exerting growth-induction, growth-inhibition, and differentiation respectively, depending on the nature of the target cells.
IL-6 is involved in
the induction of B-cell differentiation,
the induction of acute phase proteins in liver cells,
growth promotion of myeloma/plasmacytoma/hybridoma cells,
induction of IL-2 and IL-2 receptor expression,
proliferation and differentiation of T cells,
inhibition of cell growth of certain myeloid leukemic cell lines and induction of their differentiation to macrophages,
enhancement of IL-3-induced multipotential colony cell formation in hematopoietic stem cells and induction of maturation of megakaryocytes as a thrombopoietic factor,
induction of mesangial cell growth,
induction of neural differentiation of PC 12 cells and
induction of keratinocyte growth
The abnormal production of IL-6 was first suggested to be related to polyclonal B-cell activation with autoantibody production in patients with cardiac myxoma (9). Since then, IL-6 has been suggested to be involved in the pathogenesis of a variety of diseases. Measurement of IL-6 levels in serum and other body fluids thus provides more detailed insights into various pathological situations. For example:
Infections:
Body fluids of patients with acute local bacterial or viral infections and serum of patients with gram-negative or positive bacteremia contain elevated levels of biologically active IL-6 (7, 16).
Obstetric Infections:
IL-6 has emerged as a reporter cytokine for intra-amniotic infection.
Diseases associated with an altered immune system (polyclonal B-cell abnormalities or autoimmune diseases):
Elevated levels of circulating IL-6 have been detected in patients with cardiac myxoma, Castleman's disease, rheumatoid arthritis, IgM gammopathy and in those with acquired immunodeficiency syndrome as well as alcoholic liver cirrhosis.
Proliferative diseases:
Elevated plasma levels of IL-6 are observed in patients with psoriasis and mesangial proliferative glomerulonephritis.
Neoplastic Diseases:
Increased systemic levels of IL-6 have been detected in patients with multiple myeloma, other B-cell dyscrasias, Lennert's T lymphoma, Castleman's disease, renal cell carcinoma and various other solid tumors.
Inflammatory responses:
IL-6 is involved in the induction of acute phase proteins and induction of fever. Elevated serum levels of IL-6 are also found in patients with severe burns, in serum and plasma as a marker for predicting postoperative complications, in serum and urine of recipients of kidney transplants before rejection, in the serum of septic shock patients and in patients with inflammatory arthritis and traumatic arthritis.
Version 20 - 05.21
Ideal for your COVID-19 studies
855.050.000 200µg / 200µl
or by email: info [at] diaclone [dot] com ( Subject: Diaclone's order, Body: Anti-Human IL-6 Azide Free 855.050.000 - 200µg / 200µl 855.050.005 - 500µg / 500µl )